United Therapeutics (UTHR)
(Real Time Quote from BATS)
$253.52 USD
+19.19 (8.19%)
Updated May 1, 2024 02:10 PM ET
2-Buy of 5 2
B Value F Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
UTHR 253.52 +19.19(8.19%)
Will UTHR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for UTHR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for UTHR
Compared to Estimates, United Therapeutics (UTHR) Q1 Earnings: A Look at Key Metrics
What Makes United Therapeutics (UTHR) a New Buy Stock
UTHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
Stevanato Group (STVN) to Report Q1 Results: What You Should Expect
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
Other News for UTHR
UTHR Stock Earnings: United Therapeutics Beats EPS, Beats Revenue for Q1 2024
Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday
United Therapeutics: Q1 Earnings Snapshot
United Therapeutics Corporation Reports First Quarter 2024 Financial Results
United Therapeutics Surpasses Analyst Revenue Forecasts with Strong Q1 2024 Performance